Potential Fundraise: Europe targets Not applicable for market

Europe’s AI Boom Leaves Femtech Behind

Market Context

The article highlights a concerning trend in Europe’s tech investment landscape – the surge in AI funding is coinciding with a plunge in femtech (women’s health tech) investment. While global femtech investment peaked at €1.89 billion in 2021, it plummeted to just €1.1 billion the following year, as capital flooded disproportionately into the AI sector.

Strategic Implications

This imbalance in capital allocation poses serious risks for women’s health innovation in Europe. Despite projections of a €30 billion European femtech market by 2032, 44% of European femtech startups have not raised any funding at all. Talented founders with proven solutions for critical women’s health issues, such as endometriosis, menopause, and maternal health, are struggling to compete for investor attention against the “newest, shiniest” AI startups.

The article also highlights the concerning human cost of this trend, as the lack of investment in femtech solutions exacerbates existing healthcare crises. For example, the average woman with endometriosis waits seven years for a diagnosis, and up to 70% of women with polycystic ovarian syndrome (PCOS) remain undiagnosed worldwide.

PE Angle

While no specific acquisition or divestment is confirmed in the article, the broader market trends have significant implications for private equity (PE) investors and institutional investors. The disconnect between the femtech opportunity and the investment reality presents a potential value creation opportunity for PE firms willing to take a long-term view and invest in this underserved but high-growth sector.

Additionally, the article suggests that general-purpose AI solutions built without healthcare specialization can often exacerbate existing women’s health issues, highlighting the need for more targeted, femtech-focused investments to address these critical gaps.

Key Takeaways

• Europe’s AI investment boom is leaving femtech (women’s health tech) innovation behind, with femtech investment plunging from €1.89 billion in 2021 to just €1.1 billion in 2022.
• The lack of investment in femtech solutions is exacerbating existing women’s health crises, such as long delays in endometriosis diagnoses and high rates of undiagnosed polycystic ovarian syndrome (PCOS).
• The disconnect between the femtech opportunity and the investment reality presents a potential value creation opportunity for private equity firms and institutional investors willing to take a long-term view and invest in this underserved but high-growth sector.

Sources

• The Next Web